13F-HR: Pfizer Inc. Discloses Q1 2025 Investment Portfolio

Pfizer Inc. reports its holdings for the quarter ended March 31, 2025, with a total portfolio value of approximately $500.8 million across 24 holdings.

Summary

• Pfizer Inc. filed its Form 13F for the quarter ended March 31, 2025.
• The report details the company's holdings as an institutional investment manager.
• The total value of the reported holdings amounts to $500,836,847.
• The portfolio consists of 24 different holdings.
• The largest holding is Biontech SE Sponsored ADS with a value of $333,130,353 representing 3,658,361 shares.
• Allogene Therapeutics Inc COM is another significant holding with a value of $32,166,778 representing 22,032,040 shares.
• ORIC Pharmaceuticals Inc COM is valued at $30,000,000 representing 5,376,344 shares.
• Tourmaline Bio Inc COM is valued at $19,350,375 representing 1,272,214 shares.
• Wave Life Sciences LTD SHS is valued at $15,150,000 representing 1,875,000 shares.
• Biohaven LTD COM is valued at $12,155,706 representing 505,645 shares.
• Cardiff Oncology Inc COM is valued at $7,572,346 representing 2,411,575 shares.
• Pyxis Oncology Inc COMMON STOCK is valued at $5,832,623 representing 5,952,263 shares.
• Caribou Biosciences Inc COM is valued at $4,282,833 representing 4,690,431 shares.
• Zura Bio LTD CLASS A ORD SHS is valued at $3,831,328 representing 2,970,022 shares.
• Celcuity Inc COM is valued at $3,532,495 representing 349,406 shares.
• Essa Pharma Inc COM NEW is valued at $2,646,500 representing 1,675,000 shares.
• Spero Therapeutics Inc COM is valued at $1,700,891 representing 2,362,348 shares.
• Zentalis Pharmaceuticals Inc COM is valued at $1,516,596 representing 953,834 shares.
• AN2 Therapeutics Inc COM is valued at $972,801 representing 715,295 shares.
• Nextcure Inc COM is valued at $755,662 representing 1,573,312 shares.
• Q32 Bio Inc COM is valued at $458,332 representing 277,777 shares.
• Bolt Biotherapeutics Inc COM is valued at $250,444 representing 626,109 shares.
• Nextcure Inc COM is valued at $152,952 representing 318,451 shares.
• Senseonics Hldgs Inc COM is valued at $28,492 representing 43,426 shares.
• Ginkgo Bioworks Holdings Inc CL A NEW is valued at $15,282 representing 2,681 shares.
• Arvinas Inc COM is valued at $24,273,861 representing 3,457,815 shares.
• Pyxis Oncology Inc COMMON STOCK is valued at $1,058,789 representing 1,080,507 shares.
• Ginkgo Bioworks Holdings Inc CL A NEW is valued at $1,408 representing 247 shares.

Sentiment

Score: 6

Explanation: The document is a factual report of holdings. Sentiment is neutral, leaning slightly positive due to the large portfolio value, but lacks performance data.

Positives

• The document provides a detailed overview of Pfizer's investment portfolio, offering transparency into its investment strategy.
• The large value of the portfolio ($500,836,847) suggests a significant commitment to strategic investments.

Risks

• The document does not provide any performance data or analysis, making it difficult to assess the success of these investments.
• The concentration of a large portion of the portfolio in Biontech SE Sponsored ADS ($333,130,353) could pose a risk if the value of this investment declines significantly.

Industry Context

Pharmaceutical companies often invest in other biotech and pharmaceutical firms to foster innovation, gain access to new technologies, or generate financial returns. Pfizer's investment portfolio reflects this trend.

Comparison to Industry Standards

• Comparing Pfizer's investment strategy to other large pharmaceutical companies like Johnson & Johnson or Novartis would require analyzing their respective 13F filings or similar disclosures.
• Benchmarking the performance of Pfizer's investments against industry-specific venture capital or private equity funds could provide insights into its investment acumen.
• The size and composition of Pfizer's portfolio can be compared to the average investment allocations of similar-sized companies in the healthcare sector.

Stakeholder Impact

• Shareholders can gain insights into Pfizer's investment strategy and potential sources of revenue or strategic partnerships.
• The investments can support the growth and development of smaller biotech companies, potentially leading to new therapies and innovations.

Key Dates

Keywords

Form 13F, investment portfolio, holdings, Pfizer, institutional investment manager